PMID- 36830993
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230228
IS  - 2227-9059 (Print)
IS  - 2227-9059 (Electronic)
IS  - 2227-9059 (Linking)
VI  - 11
IP  - 2
DP  - 2023 Feb 4
TI  - The Impact of SGLT2 Inhibitor Dapagliflozin on Adropin Serum Levels in Men and 
      Women with Type 2 Diabetes Mellitus and Chronic Heart Failure.
LID - 10.3390/biomedicines11020457 [doi]
LID - 457
AB  - BACKGROUND: adropin plays a protective role in cardiac remodeling through 
      supporting energy metabolism and water homeostasis and suppressing inflammation. 
      Low circulating levels of adropin were positively associated with the risk of 
      cardiovascular diseases and type 2 diabetes mellitus (T2DM). We hypothesized that 
      sodium-glucose linked transporter 2 (SGLT2) inhibitor dapagliflosin might 
      represent cardiac protective effects in T2DM patients with known chronic HF 
      through the modulation of adropin levels. METHODS: we prospectively enrolled 417 
      patients with T2DM and HF from an entire cohort of 612 T2DM patients. All 
      eligible patients were treated with the recommended guided HF therapy according 
      to their HF phenotypes, including SGLT2 inhibitor dapagliflozin 10 mg, daily, 
      orally. Anthropometry, clinical data, echocardiography/Doppler examinations, and 
      measurements of biomarkers were performed at the baseline and over a 6-month 
      interval of SGLT2 inhibitor administration. RESULTS: in the entire group, 
      dapagliflozin led to an increase in adropin levels by up to 26.6% over 6 months. 
      In the female subgroup, the relative growth (Delta%) of adropin concentrations was 
      sufficiently higher (Delta% = 35.6%) than that in the male subgroup (Delta% = 22.7%). A 
      multivariate linear regression analysis of the entire group showed that the 
      relative changes (Delta) in the left ventricular (LV) ejection fraction (LVEF), left 
      atrial volume index (LAVI), and E/e' were significantly associated with increased 
      adropin levels. In the female subgroup, but not in the male subgroup, DeltaLVEF (p = 
      0.046), DeltaLAVI (p = 0.001), and DeltaE/e' (p = 0.001) were independent predictive 
      values for adropin changes. CONCLUSION: the levels of adropin seem to be a 
      predictor for the favorable modification of hemodynamic performances during SGLT2 
      inhibition, independent ofN-terminal brain natriuretic pro-peptide levels.
FAU - Berezin, Alexander A
AU  - Berezin AA
AD  - Internal Medicine Department, Zaporozhye Medical Academy of Postgraduate 
      Education, 69000 Zaporozhye, Ukraine.
AD  - Department of Psychosomatic Medicine and Psychotherapy, Klinik Barmelweid, 5017 
      Barmelweid, Switzerland.
FAU - Obradovic, Zeljko
AU  - Obradovic Z
AD  - Department of Psychosomatic Medicine and Psychotherapy, Klinik Barmelweid, 5017 
      Barmelweid, Switzerland.
FAU - Fushtey, Ivan M
AU  - Fushtey IM
AD  - Internal Medicine Department, Zaporozhye Medical Academy of Postgraduate 
      Education, 69000 Zaporozhye, Ukraine.
FAU - Berezina, Tetiana A
AU  - Berezina TA
AD  - Department of Internal Medicine and Nephrology, VitaCenter, 69000 Zaporozhye, 
      Ukraine.
FAU - Novikov, Evgen V
AU  - Novikov EV
AD  - Educational and Research Center-Ukrainian Family Medicine Training Center, 
      Bogomolets National Medical University, 01601 Kyiv, Ukraine.
FAU - Schmidbauer, Lukas
AU  - Schmidbauer L
AD  - Department of Internal Medicine II, Division of Cardiology, Paracelsus Medical 
      University Salzburg, 5020 Salzburg, Austria.
FAU - Lichtenauer, Michael
AU  - Lichtenauer M
AD  - Department of Internal Medicine II, Division of Cardiology, Paracelsus Medical 
      University Salzburg, 5020 Salzburg, Austria.
FAU - Berezin, Alexander E
AU  - Berezin AE
AUID- ORCID: 0000-0002-0446-3999
AD  - Department of Internal Medicine II, Division of Cardiology, Paracelsus Medical 
      University Salzburg, 5020 Salzburg, Austria.
AD  - Internal Medicine Department, Zaporozhye State Medical University, 69035 
      Zaporozhye, Ukraine.
LA  - eng
PT  - Journal Article
DEP - 20230204
PL  - Switzerland
TA  - Biomedicines
JT  - Biomedicines
JID - 101691304
PMC - PMC9953100
OTO - NOTNLM
OT  - adropin
OT  - dapagliflosin
OT  - heart failure
OT  - hemodynamics
OT  - natriuretic peptide
OT  - type 2 diabetes mellitus
COIS- The authors declare no conflict of interest.
EDAT- 2023/02/26 06:00
MHDA- 2023/02/26 06:01
PMCR- 2023/02/04
CRDT- 2023/02/25 01:28
PHST- 2023/01/04 00:00 [received]
PHST- 2023/01/31 00:00 [revised]
PHST- 2023/02/01 00:00 [accepted]
PHST- 2023/02/25 01:28 [entrez]
PHST- 2023/02/26 06:00 [pubmed]
PHST- 2023/02/26 06:01 [medline]
PHST- 2023/02/04 00:00 [pmc-release]
AID - biomedicines11020457 [pii]
AID - biomedicines-11-00457 [pii]
AID - 10.3390/biomedicines11020457 [doi]
PST - epublish
SO  - Biomedicines. 2023 Feb 4;11(2):457. doi: 10.3390/biomedicines11020457.